AJIC: American Journal of Infection Control
Volume 31, Issue 1 , Pages 1-8 , February 2003

Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use

References 

  1. Raad II , Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis. 1992;15:197–208
  2. Maki DG. Infections caused by intravascular devices used for infusion therapy. In: 2nd ed.  Bistro AI,  Waldvogel FA editor. Infections associated with indwelling medical devices. Washington (DC): ASM Press; 1994;p. 155–205
  3. Martin MA, Pfaller MA, Wenzel RP. Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. Ann Intern Med. 1989;110:9–16
  4. Arnow PM, Quimosing EM, Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis. 1993;16:778–784
  5. Smith RL, Meixler SM, Simberkoff MS. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest. 1991;100:164–167
  6. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598–1601
  7. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al.  Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group Ann Intern Med. 1997;127:267–274
  8. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA. 1999;281:261–267
  9. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA. 1999;282:554–560
  10. Wenzel RP, Edmond MB. The evolving technology of venous access. N Engl J Med. 1999;340:48–50
  11. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med. 2000;132:391–402
  12. Guideline for prevention of intravascular device-related infections . Part II. Recommendations for the prevention of nosocomial intravascular device-related infections. Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1996;24:277–293
  13. Darouiche RO, Raad II , Heard SO, Thornby JI, Wenker OC, Gabrielli A, et al.  A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340:1–8
  14. dos Santos CC, Stewart TE, McGeer A. Anti-microbial or antiseptic impregnated central venous catheters: update on a “central” debate. Intensive Care Med. 2000;26:246–249
  15. Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful?. Infect Control Hosp Epidemiol. 2000;21:375–380
  16. Spencer RC. Novel methods for the prevention of infection of intravascular devices. J Hosp Infect. 1999;43(suppl):S127–S135
  17. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: part 1—getting started. Med Decis Making. 1997;17:123–125
  18. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: part 2—building a tree. Med Decis Making. 1997;17:126–135
  19. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995;6:356–365
  20. Tacconelli E, Tumbarello M, Pittiruti M, Leone F, Lucia MB, Cauda R, et al.  Central venous catheter-related sepsis in a cohort of 366 hospitalised patients. Eur J Clin Microbiol Infect Dis. 1997;16:203–209
  21. Niskanen M, Kari A, Halonen P, the Finnish ICU Study Group . Five-year survival after intensive care—comparison of 12,180 patients with the general population. Crit Care Med. 1996;24:1962–1967
  22. NNIS System . National Nosocomial Infections Surveillance (NNIS) System Report, data summary from October 1986-April 1998. Atlanta (Ga): Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services; June 1998;
  23. Centers for Disease Control and Prevention . National vital statistics report. Available at http://www.cdc.gov/nchs/data/nvsr/nvsr47/nvs47_28.pdf1999;
  24. Norum J, Angelsen V, Wist E, Olsen JA. Treatment costs in Hodgkin's disease: a cost-utility analysis. Eur J Cancer. 1996;32A:1510–1517
  25. Kavanagh T, Myers MG, Baigrie RS, Mertens DJ, Sawyer P, Shephard RJ. Quality of life and cardiorespiratory function in chronic heart failure: effects of 12 months' aerobic training. Heart. 1996;76:42–49
  26. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583–637
  27. Gold MR, Siegal JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996;
  28. Bureau of Labor Statistics. Consumer price index 2000. Available at: http://146.142.4.24/cgi-bin/surveymost
  29. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1–31
  30. Krahn MD, Naglie G, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 4—analyzing the model and interpreting the results. Med Decis Making. 1997;17:142–151
  31. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1985;5:157–177
  32. Cook Critical Care . Catheter related septicemia: magnitude of the problem. Available at http://www.grii.cpm/cook_critical_care/product_news/spectrum.html2000;
  33. Maki DG, Stoltz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. Ann Intern Med. 1997;127:257–266
  34. Renaud B, Brun-Buisson C. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med. 2001;163:1584–1590
  35. Rello J, Ochagavia A, Sabanes E, Roque M, Mariscal D, Reynaga E, et al.  Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med. 2000;162:1027–1030
  36. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol. 1999;20:396–401
  37. Paterson DL. Antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340:1761
  38. Bach A. Antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340:1761
  39. Potential hypersensitivity reactions to chlorhexidine-impregnated medical devices. Center for Devices and Radiological Health Available at http://www.fda.gov/cdrh/chlorhex.html2000;
  40. World Health Organization . Central venous catheters (Arrowgard) recalled: anaphylactic shock. Information exchange system alert No. 62. Geneva: Switzerland: WHO; 1997;
  41. Yasukawa T, Fujita Y, Sari A. Antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340:1762
  42. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis. 1996;173:418–424

☆ Dr Saint was supported by a Career Development Award from the VA Health Services Research and Development Service during the time much of this work was completed.

☆☆ Reprint requests: David L. Veenstra, PharmD, PhD, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195.

PII: S0196-6553(02)48235-1

doi: 10.1067/mic.2003.35

AJIC: American Journal of Infection Control
Volume 31, Issue 1 , Pages 1-8 , February 2003

Article Tools

* Image Usage & Resolution